Effect of SRSF2 gene mutation on the prognosis of myelodysplastic syndromes: a Meta-analysis / 肿瘤研究与临床

ABSTRACT

Objective:To systematically evaluate the effect of SRSF2 gene mutation on the prognosis of patients with myelodysplastic syndromes (MDS).Methods:Databases including PubMed, Embase and Cochrane Library were searched for relevant studies that conducted the effect of SRSF2 gene mutation on the prognosis of MDS. The retrieval time limit was from the time of establishing database to December 2018. All cohort studies related to the effect of SRSF2 gene mutation on the prognosis of MDS were screened according to the inclusion and exclusion criteria. Data extraction and bias risk assessment were conducted for the eligible literature. The observation indicators were statistically analyzed by using RevMan 5.3 software.Results:A total of 11 studies were included in the final Meta-analysis. Compared with MDS patients without SRSF2 mutation, MDS patients with SRSF2 mutation had shorter overall survival time (HR = 1.67, 95% CI 1.40-2.00, P < 0.01) and progression-free survival time (HR = 6.20, 95% CI 2.64-14.58, P < 0.01). MDS patients with SRSF2 mutation was easier to transform into acute myeloid leukemia (AML) with shorter time (HR = 2.02, 95% CI 1.49-2.74, P < 0.01) compared to patients without SRSF2 mutation.Conclusion:SRSF2 gene mutation is an independent poor prognosis factor in patients with MDS.